Table 1.
Patient population.
| Number of patients: 39 (100%) | |
|---|---|
| Clinical | |
| Gender | |
| Male | 23 (59%) |
| Female | 16 (41%) |
| Age (years), mean ± standard deviation | 57.91 ± 16.02 (range 17–82) |
| Smoking status | |
| Never smoker | 17 (43.6%) |
| Former/current smoker | 22 (56.4%) |
| Pathological | |
| WHO histology | |
| Squamous cell TC | 29 (74.4%) |
| Undifferentiated TC | 8 (21.5%) |
| Lymphoepithelioma-like carcinoma | 2 (5.1%) |
| Masaoka–Koga stage | |
| I | 2 (5.1%) |
| II | 10 (25.7%) |
| III | 14 (35.9%) |
| IV | 13 (33.3%) |
| pTNM stage (eighth ed.) | |
| I/II | 13 (33.3%) |
| III/IV | 26 (66.7%) |
| Myasthenia gravis | 2 (5.1%) |
| Resection status | |
| R0 | 32 (82.1%) |
| R1/R2 | 7 (17.9%) |
| Treatment | |
| Induction treatments | |
| None | 20 (51.3%) |
| Chemotherapy (ChT) | 17 (43.5%) |
| Radiotherapy (RT) | 2 (5.2%) |
| Adjuvant treatments | |
| None | 13 (33.3) |
| Chemotherapy (ChT) | 7 (18%) |
| Radiotherapy (RT) | 19 (48.7%) |
| Survival (months) mean ± SD | |
| Freedom from recurrence | 38.3 ± 49 |
| Cause-specific survival | 43.1 ± 46 |
| Overall survival | 46.5 ± 45 |